Swedish Orphan Biovitrum : Sobi publishes Annual and sustainability report for 2023
April 02, 2024 at 02:37 pm IST
Share
English
Published: 2024-04-02 11:00:00 CEST
Swedish Orphan Biovitrum AB
Annual Financial Report
Sobi publishes Annual and sustainability report for 2023
Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and sustainability report for 2023. Inspired by caring and powered by science, the integrated report summarises business and strategy, financial performance, and work on sustainability.
The report includes the audited Annual report and the Sustainability report, which is Sobi's statutory sustainability report in accordance with the Swedish Annual Accounts Act and based on GRI Standards 2021. The Sustainability report includes Sobi's Task Force on Climate-related Financial Disclosures (TCFD) report and the EU taxonomy disclosures.
Sobi's 2023 Annual and Sustainability Report is available onsobi.com. The Swedish Annual Report is also available in European Single Electronic Format (ESEF).
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com andLinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please clickhere. For Sobi Media contacts, clickhere.
Gerard Tobin
Head of Investor Relations
Attachments:
03273912.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original Link
Permalink
Disclaimer
Swedish Orphan Biovitrum AB published this content on
02 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
02 April 2024 09:06:07 UTC.
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.